Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 12/20 | 0.36 |
| ▸ | JAK1 | P23458 | 11/20 | 0.36 |
| ▸ | JAK2 | O60674 | 8/20 | 0.34 |
| ▸ | TYK2 | P29597 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15889075 | 0.89 | JAK1 (0.38) | HTTMAP3K5JAK3JAK1JAK2 | |
| SCHEMBL4569237 | 0.82 | JAK3 (0.35) | JAK3JAK1JAK2TYK2IRAK4 | |
| SCHEMBL14564406 | 0.82 | JAK3 (0.44) | JAK3JAK1JAK2TYK2CSF1R | |
| SCHEMBL9589430 | 0.81 | JAK1 (0.52) | JAK3JAK1JAK2TYK2IRAK4 | |
| SCHEMBL21814339 | 0.79 | HTT (0.58) | HTTMAP3K5NCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL4572187 | 0.78 | HTT (0.45) | HTTMAP3K5NCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL4572193 | 0.77 | HTT (0.51) | HTTMAP3K5NCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL9827168 | 0.74 | JAK3 (0.39) | HTTJAK3JAK1JAK2TYK2 | |
| SCHEMBL23897679 | 0.74 | CSF1R (0.38) | JAK3JAK1JAK2TYK2CSF1R | |
| SCHEMBL5019515 | 0.72 | HTT (0.41) | HTTMAP3K5NCOA1SMN1; SMN2NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | HTT 823/4885MAP3K5 53/4885NCOA1 1107/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | HTT 996/4885MAP3K5 52/4885NCOA1 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.